Media Release

News Release
Zofingen, 13 May 2015
Siegfried: RAG-Stiftung Beteiligungsgesellschaft mbH to participate
in financing of latest acquisition
(SIX: SFZN) RAG-Stiftung Beteiligungsgesellschaft mbH based in Essen, Germany, will participate in a hybrid bond of Siegfried Holding AG in order to financing Siegfried’s acquisition
of significant elements of BASF’s pharmaceutical supply business. The bond entitles RAGStiftung to convert the amount within 5 years into Siegfried Holding AG shares, which represents a stake in Siegfried of about 7 percent. It is expected that the stock will come from
Siegfried Holding AG’s own holding. A capital increase is not planned in this connection.
Siegfried CEO Rudolf Hanko: “RAG-Stiftung Beteiligungsgesellschaft mbH is a stable partner
with a long-term focus and in full support of the Siegfried Group’s strategy.”
For further information:
Peter Gehler, Chief Communications Officer
[email protected]
Phone +41 (0)62 746 11 48
Mobile +41 (0)79 416 41 16
Siegfried Holding AG
Untere Brühlstrasse 4
CH-4800 Zofingen
Tel. +41 (0)62 746 11 11
Fax +41 (0)62 746 11 03
www.siegfried.ch
About Siegfried
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, Germany, China, Malta and in the USA. At the end of 2014, Siegfried reported annual sales of CHF 315
million and employs at the time being approximately 1400 employees. Siegfried Holding AG is listed on the Swiss
Exchange (SIX: SFZN).
Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediate steps and controlled substances, and provides development and production services for
drugs in finished dosage forms including sterile filling.
1

Download Report